Special Drug Use-results Surveillance of Tabrecta Tablets

Special Drug Use-results Surveillance of Tabrecta Tablets (MET Exon 14 Skipping Mutation-positive Unresectable Advanced/Recurrent Non-small Cell Lung Cancer)

ClinicalTrials.gov Identifier: NCT04575025

Novartis Reference Number: CINC280AJP01

Last Update: Nov 10, 2021

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

This study is an uncontrolled, primary data collection-based observational study to be conducted as a central registration system, multicenter special drug-use results surveillance. As an all-case study, this study will collect all patients treated with Tabrecta in a specified post-marketing period. The observation period of each patient is up to 1 year (52 weeks)

Condition

Non-small Cell Lung Cancer

Phase

Not Given

Overall status

Recruiting

Enrollment count

100 participants

Start date

Nov 02, 2020

Completion date

Sep 29, 2023

Gender

All

Age(s)

99 Years and older (Child, Adult, Older Adult)

Interventions

Drug

Tabrecta tablets

There is no treatment allocation. Patients administered Tabrecta by prescription that have started before inclusion of the patient into the study will be enrolled.

Eligibility Criteria

Inclusion Criteria:

All patients receiving Tabrecta for MET exon 14 skipping mutation-positive unresectable advanced/recurrent NSCLC during a specified post-marketing period

Exclusion Criteria: